Heghine Khachatryan: What EHA 2026 Reveals About the Future of Aplastic Anemia Treatment
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared American Society of Hematology’s post on LinkedIn:
“Aplastic Anemia in 2026: Moving Beyond Traditional IST
The management of severe aplastic anemia continues to evolve.
While horse ATG plus cyclosporine remains the backbone of frontline immunosuppressive therapy, recent studies and EHA 2026 discussions highlight the growing role of thrombopoietin receptor agonists (especially eltrombopag) in improving hematologic responses and reducing transfusion dependence.
Key trends shaping 2026 practice include:
- Earlier integration of TPO-receptor agonists into frontline therapy
- Improved risk stratification through molecular profiling and clonal evolution monitoring
- More individualized treatment selection based on age, donor availability, and genomic findings
- Ongoing refinement of the balance between immunosuppression and stem cell transplantation strategies
The future of aplastic anemia treatment is increasingly focused on precision medicine, deeper responses, and long-term prevention of clonal progression.”
American Society of Hematology shared a post on LinkedIn:
“How is frontline immunosuppressive therapy for aplastic anemia evolving in 2026?
Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from EHA 2026 and practical, evidence-based strategies for patient management.
June 18 | 6–7 p.m.
Register now.”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin
-
Aug 10, 2026, 15:47Edward Lee Carter: 61% of Patients on Reduced-Dose Apixaban Did Not Meet Label Criteria